BridgeBio Pharma, Inc. BBIO
7 trading plans running, 29 Form 144 notices for $91.5M
10-Q, 10-K and Form 144What BBIO's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Mar 31, 2025 to Sep 4, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Charles Homcy Chairman of Pharmaceuticals and Lead Director on our Board of Directors |
Adopted 10b5-1 plan | Sep 4, 2026 | 10-Q Oct 29, 2026 | ||
What the company wroteOn September 4, 2026, Charles Homcy, our Chairman of Pharmaceuticals and Lead Director on our Board of Directors, adopted a trading plan (the “Homcy Trading Plan”) intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). The Homcy Trading Plan provides for the potential sale of an aggregate of 120,000 shares of our common stock underlying the stock options held by Dr. Homcy. Dr. Homcy is not permitted to transfer, sell or otherwise dispose of any shares under the Homcy Trading Plan until the Earliest Sell Date, which is the later of (i) the 91st day after the adoption date of the Homcy Trading Plan; or (ii) the earlier of: (a) the third business day following the disclosure of the Company’s financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the Homcy Trading Plan is adopted; or (b) the 121st day after the adoption date. The Homcy Trading Plan is expected to remain in effect until the earlier of (a) September 4, 2027; (b) the first date on which all trades have been executed or all trading orders relating to such trades set forth in Addendum A to the Homcy Trading Plan have expired; (c) as soon as practicable following the date on which Dr. Homcy gives written notice to Morgan Stanley Smith Barney LLC (“MSSB”) to terminate the Homcy Trading Plan; (d) as soon as practicable following the date on which MSSB receives written notice of a termination of an additional contract, instruction or plan that is being treated as a single “plan” with the Homcy Trading Plan (or MSSB receives written notice of a modification of such additional contract, instruction or plan and the requirements for a modification of the Homcy Trading Plan are not or cannot be satisfied); (e) as soon as practicable following the date on which MSSB receives written notice of a legal, regulatory or contractual restriction applicable to the Company or to Dr. Homcy that would result in a modification or change to the amount, price or timing of the sale of shares under the Homcy Trading Plan but the requirements for a modification of the Homcy Trading Plan are not or cannot be satisfied; and (f) as soon as practicable following the date on which MSSB receives notice of certain events, including the public announcement of a tender or exchange offer with respect to the Company’s common stock or that the Company is the target of a merger, acquisition, reorganization, recapitalization or comparable transaction as a result of which the Company’s common stock will be converted into shares of another company, or the commencement of bankruptcy or insolvency proceeding with respect to the Company. | |||||
| Neil Kumar Chief Executive Officer and a member of our Board of Directors |
Adopted 10b5-1 plan | May 13, 2026 | 10-Q Aug 10, 2026 | ||
What the company wroteOn May 13, 2026, Neil Kumar, our Chief Executive Officer and a member of our Board of Directors, adopted a trading plan (the “Kumar Trading Plan”) intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). The Kumar Trading Plan provides for the potential sale of (i) a number of shares of our common stock to be determined based on the net shares resulting from the vesting of restricted stock units and performance stock units held by Dr. Kumar, representing 100% of the net shares vested under each applicable grant, and (ii) up to 120,000 shares of our common stock held by the Kumar Haldea Family Irrevocable Trust, of which Dr. Kumar is a trustee. Dr. Kumar and the Kumar Haldea Family Irrevocable Trust are not permitted to transfer, sell or otherwise dispose of any shares under the Kumar Trading Plan until the Earliest Sell Date, which is the later of (i) the 91st day after the adoption date of the Kumar Trading Plan; or (ii) the earlier of: (a) the third business day following the disclosure of the Company’s financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the Kumar Trading Plan is adopted; or (b) the 121st day after the adoption date. The Kumar Trading Plan is expected to remain in effect until the earlier of (a) July 30, 2027; (b) the first date on which all trades have been executed or all trading orders relating to such trades set forth in Part II of the Kumar Trading Plan have expired; (c) as soon as practicable following the date on which Dr. Kumar gives written notice to Morgan Stanley Smith Barney LLC (“MSSB”) to terminate the Kumar Trading Plan; (d) as soon as practicable following the date on which MSSB receives written notice of a termination of an additional contract, instruction or plan that is being treated as a single “plan” with the Kumar Trading Plan (or MSSB receives written notice of a modification of such additional contract, instruction or plan and the requirements for a modification of the Kumar Trading Plan are not or cannot be satisfied); (e) as soon as practicable following the date on which MSSB receives written notice of a legal, regulatory or contractual restriction applicable to the Company or to Dr. Kumar that would result in a modification or change to the amount, price or timing of the sale of shares under the Kumar Trading Plan but the requirements for a modification of the Kumar Trading Plan are not or cannot be satisfied; and (f) as soon as practicable following the date on which MSSB receives notice of certain events, including the public announcement of a tender or exchange offer with respect to the Company’s common stock or that the Company is the target of a merger, acquisition, reorganization, recapitalization or comparable transaction as a result of which the Company’s common stock will be converted into shares of another company, or the commencement of bankruptcy or insolvency proceeding with respect to the Company. | |||||
| Jennifer Cook member of our Board of Directors |
Adopted 10b5-1 plan | Mar 16, 2026 | 10-Q May 7, 2026 | ||
What the company wroteOn March 16, 2026, Jennifer Cook, a member of our Board of Directors, adopted a trading plan (the “Cook Trading Plan”) intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). The Cook Trading Plan provides for the potential sale of a maximum of (i) 7,152 shares of our common stock held by Ms. Cook and (ii) 351,722 shares of our common stock underlying stock options held by Ms. Cook. Ms. Cook is not permitted to transfer, sell or otherwise dispose of any shares under the Cook Trading Plan until the Earliest Sell Date, which is the later of (i) the 91st day after the adoption date of the Cook Trading Plan; or (ii) the earlier of: (a) the third business day following the disclosure of the Company’s financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the Cook Trading Plan is adopted; or (b) the 121st day after the adoption date. The Cook Trading Plan is expected to remain in effect until the earlier of (a) June 15, 2027; (b) the first date on which all trades have been executed or all trading orders relating to such trades set forth on Addendum A of the Cook Trading Plan have expired; (c) as soon as practicable following the date on which Ms. Cook gives written notice to Morgan Stanley Smith Barney LLC (“MSSB”) to terminate the Cook Trading Plan; (d) as soon as practicable following the date on which MSSB receives written notice of a termination of an additional contract, instruction or plan that is being treated as a single “plan” with the Cook Trading Plan (or MSSB receives written notice of a modification of such additional contract, instruction or plan and the requirements for a modification of the Cook Trading Plan are not or cannot be satisfied); (e) as soon as practicable following the date on which MSSB receives written notice of a legal, regulatory or contractual restriction applicable to the Company or to Ms. Cook that would result in a modification or change to the amount, price or timing of the sale of shares under the Cook Trading Plan but the requirements for a modification of the Cook Trading Plan are not or cannot be satisfied; and (f) as soon as practicable following the date on which MSSB receives notice of certain events, including the public announcement of a tender or exchange offer with respect to the Company’s common stock or that the Company is the target of a merger, acquisition, reorganization, recapitalization or comparable transaction as a result of which the Company’s common stock will be converted into shares of another company, or the commencement of bankruptcy or insolvency proceeding with respect to the Company. | |||||
| Dr. Frank McCormick member of our Board of Directors |
Adopted 10b5-1 plan | Dec 4, 2025 | 10-K Feb 24, 2026 | ||
What the company wroteOn December 4, 2025, Dr. Frank McCormick, a member of our Board of Directors, adopted a trading plan on behalf of the Francis P. McCormick Revocable Trust U/A DTD 1/27/2017, of which Dr. McCormick is a trustee, for the sale of a maximum of 200,000 shares of our common stock (the “McCormick Trading Plan”). The McCormick Trading Plan is intended to satisfy the affirmative defense conditions of the Securities and Exchange Act Rule 10b5-1(c) and is expected to take effect on March 6, 2026 and remain in effect until the earlier of (1) March 5, 2027 and (2) the date on which an aggregate of 200,000 shares of our common stock have been sold under such McCormick Trading Plan. | |||||
| Ms. Andrea J. Ellis member of our Board of Directors |
Adopted 10b5-1 plan | Dec 3, 2025 | 10-K Feb 24, 2026 | ||
What the company wroteOn December 3, 2025, Ms. Andrea J. Ellis, a member of our Board of Directors, adopted a trading plan (the “Ellis Trading Plan”) intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). The Ellis Trading Plan provides for the potential sale of an aggregate of 82,088 shares of our common stock underlying the stock options held by Ms. Ellis. Ms. Ellis is not permitted to transfer, sell or otherwise dispose of any shares under the Ellis Trading Plan until the Earliest Sell Date, which is the later of (i) the 91st day after the adoption date of the Ellis Trading Plan; or (ii) the earlier of: (a) the third business day following the disclosure of the Company’s financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the Ellis Trading Plan is adopted; or (b) the 121st day after the adoption date. The Ellis Trading Plan is expected to remain in effect until the earlier of (a) November 30, 2026; (b) the first date on which all trades have been executed or all trading orders relating to such trades set forth on Addendum A of the Ellis Trading Plan have expired; (c) as soon as practicable following the date on which Ms. Ellis gives written notice to MSSB to terminate the Ellis Trading Plan; (d) as soon as practicable following the date on which MSSB receives written notice of a termination of an additional contract, instruction or plan that is being treated as a single “plan” with the Ellis Trading Plan (or MSSB receives written notice of a modification of such additional contract, instruction or plan and the requirements for a modification of the Ellis Trading Plan are not or cannot be satisfied); (e) as soon as practicable following the date on which MSSB receives written notice of a legal, regulatory or contractual restriction applicable to the Company or to Ms. Ellis that would result in a modification or change to the amount, price or timing of the sale of shares under the Ellis Trading Plan but the requirements for a modification of the Ellis Trading Plan are not or cannot be satisfied; and (f) as soon as practicable following the date on which MSSB receives notice of certain events, including the public announcement of a tender or exchange offer with respect to the Company’s common stock or that the Company is the target of a merger, acquisition, reorganization, recapitalization or comparable transaction as a result of which the Company’s common stock will be converted into shares of another company, or the commencement of bankruptcy or insolvency proceeding with respect to the Company. | |||||
| Dr. Hannah A. Valantine member of our Board of Directors |
Adopted 10b5-1 plan | Nov 14, 2025 | 10-K Feb 24, 2026 | ||
What the company wroteOn November 14, 2025, Dr. Hannah A. Valantine, a member of our Board of Directors, adopted a trading plan (the “Valantine Trading Plan”) intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). The Valantine Trading Plan provides for the potential sale of a maximum of (i) 36,963 shares of our common stock underlying the stock options held by Dr. Valantine and (ii) 100% of net vested shares of our common stock to be issued to Dr. Valantine upon vesting of her restricted stock units (“RSUs”) on June 20, 2026. On the date when the Valantine Trading Plan was adopted, Dr. Valantine held no such net vested shares. Dr. Valantine’s net vested share amount will change as additional RSUs vest on the applicable vesting date. The aggregate number of net vested shares of common stock that will be available for sale by Dr. Valantine is not yet determinable because the shares available will be net of shares to be withheld to satisfy tax obligations in connection with the vesting of her RSUs on the vesting date. Dr. Valantine is not permitted to transfer, sell or otherwise dispose of any shares under the Valantine Trading Plan until the Earliest Sell Date, which is the later of (i) the 91st day after the adoption date of the Valantine Trading Plan; or (ii) the earlier of: (a) the third business day following the disclosure of the Company’s financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the Valantine Trading Plan is adopted; or (b) the 121st day after the adoption date. The Valantine Trading Plan is expected to remain in effect until the earlier of (a) December 31, 2026; (b) the first date on which all trades have been executed or all trading orders relating to such trades set forth on Addendum A of the Valantine Trading Plan have expired; (c) as soon as practicable following the date on which Dr. Valantine gives written notice to Morgan Stanley Smith Barney LLC (“MSSB”) to terminate the Valantine Trading Plan; (d) as soon as practicable following the date on which MSSB receives written notice of a termination of an additional contract, instruction or plan that is being treated as a single “plan” with the Valantine Trading Plan (or MSSB receives written notice of a modification of such additional contract, instruction or plan and the requirements for a modification of the Valantine Trading Plan are not or cannot be satisfied); (e) as soon as practicable following the date on which MSSB receives written notice of a legal, regulatory or contractual restriction applicable to the Company or to Dr. Valantine that would result in a modification or change to the amount, price or timing of the sale of shares under the Valantine Trading Plan but the requirements for a modification of the Valantine Trading Plan are not or cannot be satisfied; and (f) as soon as practicable following the date on which MSSB receives notice of certain events, including the public announcement of a tender or exchange offer with respect to the Company’s common stock or that the Company is the target of a merger, acquisition, reorganization, recapitalization or comparable transaction as a result of which the Company’s common stock will be converted into shares of another company, or the commencement of bankruptcy or insolvency proceeding with respect to the Company. | |||||
| Maricel M. Apuli Chief Accounting Officer |
Adopted 10b5-1 plan | Sep 8, 2025 | 10-Q Oct 29, 2025 | ||
What the company wroteOn September 8, 2025, Maricel M. Apuli, our Chief Accounting Officer, adopted a trading plan (the “Trading Plan”), intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). The Trading Plan provides for the potential sale of a maximum of (i) 10,000 vested shares of our restricted stock held by Ms. Apuli, and (ii) 100% of net purchased shares of our common stock to be purchased by Ms. Apuli under the ESPP on February 13, 2026, and August 15, 2026, respectively. On the date when the Trading Plan was adopted, Ms. Apuli did not hold any such shares to be purchased under the ESPP. The aggregate number of net purchased shares of common stock under the ESPP that will be available for sale by Ms. Apuli is not yet determinable because the number of shares purchased will be based on the applicable per share purchase price under the ESPP on the purchasing date. Ms. Apuli is not permitted to transfer, sell or otherwise dispose of any shares under the Trading Plan until the later of (i) the 91st day after the adoption date of the Trading Plan (i.e. December 8, 2025), or (ii) the earlier of: (a) the third business day following the disclosure of the Company’s financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the Trading Plan is adopted (estimated October 29, 2025); or (b) the 121 st day after the adoption date of the Trading Plan (estimated January 7, 2026). The Trading Plan is expected to remain in effect until the earlier of (a) November 17, 2026; (b) the first date on which all trades have been executed or all trading orders relating to such trades set forth on Addendum A of the Trading Plan have expired; (c) as soon as practicable following the date on which Ms. Apuli gives written notice to Morgan Stanley Smith Barney LLC (“MSSB”) to terminate the Trading Plan; (d) as soon as practicable following the date on which MSSB receives written notice of a termination of an additional contract, instruction or plan that is being treated as a single “plan” with the Trading Plan (or MSSB receives written notice of a modification of such additional contract, instruction or plan and the requirements for a modification of the Trading Plan are not or cannot be satisfied); (e) as soon as practicable following the date on which MSSB receives written notice of a legal, regulatory or contractual restriction applicable to the Company or to Ms. Apuli that would result in a modification or change to the amount, price or timing of the sale of shares under the Trading Plan but the requirements for a modification of the Trading Plan are not or cannot be satisfied; and (f) as soon as practicable following the date on which MSSB receives notice of certain events, including the public announcement of a tender or exchange offer with respect to the Company’s common stock or that the Company is the target of a merger, acquisition, reorganization, recapitalization or comparable transaction as a result of which the Company’s common stock will be converted into shares of another company, or the commencement of bankruptcy or insolvency proceeding with respect to the Company. | |||||
| Randal W. Scott, Ph.D Board of Directors |
Adopted 10b5-1 plan | Jun 27, 2025 | 10-Q Aug 5, 2025 | ||
| Dr. Charles J. Homcy Board of Directors |
Adopted 10b5-1 plan | May 8, 2025 | 10-Q Aug 5, 2025 | ||
| Dr. Neil Kumar Chief Executive Officer |
Adopted 10b5-1 plan | Mar 31, 2025 | 10-Q Apr 29, 2025 | ||
| Thomas Trimarchi President and Chief Financial Officer |
Adopted 10b5-1 plan | Mar 31, 2025 | 10-Q Apr 29, 2025 | ||
| Andrea Ellis Director |
Adopted 10b5-1 plan | Dec 30, 2024 | 10-K Feb 20, 2025 | ||
| Hannah A. Valantine Director |
Adopted 10b5-1 plan | Dec 5, 2024 | 10-K Feb 20, 2025 | ||
| Frank McCormick Board of Directors |
Adopted 10b5-1 plan | Aug 30, 2024 | 10-Q Nov 12, 2024 | ||
| Dr. Brian Stephenson Chief Financial Officer |
Adopted 10b5-1 plan | Mar 22, 2024 | 10-Q May 2, 2024 | ||
| Dr. Neil Kumar Chief Executive Officer |
Adopted 10b5-1 plan | Mar 22, 2024 | 10-Q May 2, 2024 | ||
| Dr. Charles J. Homcy Board of Directors |
Adopted 10b5-1 plan | Mar 7, 2024 | 10-Q May 2, 2024 | ||
| Dr. Hannah A. Valantine Board of Directors |
Ended 10b5-1 plan | Mar 7, 2024 | 10-Q May 2, 2024 | ||
| Hannah A. Valantine Board of Directors |
Adopted 10b5-1 plan | Aug 16, 2023 | 10-Q Nov 2, 2023 | ||
| Frank McCormick Board of Directors |
Adopted 10b5-1 plan | Jun 15, 2023 | 10-Q Aug 3, 2023 | ||
| Randal W. Scott, Ph.D Board of Directors |
Adopted 10b5-1 plan | Jun 6, 2023 | 10-Q Aug 3, 2023 | ||
Show the other 13 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 4, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Aug 19, 2026 | KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 Director, Officer |
30,000 | $2.5M |
| Aug 18, 2026 | NEIL KUMAR Director, Officer |
34,980 | $2.8M |
| Aug 17, 2026 | RANDAL SCOTT Director |
21,501 | $1.7M |
| Jul 9, 2026 | JENNIFER COOK Director |
148,589 | $13.2M |
| Jul 9, 2026 | ANDREA ELLIS Director |
17,167 | $1.4M |
| Jun 24, 2026 | RANDAL SCOTT Director |
2,196 | $151K |
| Jun 24, 2026 | JENNIFER COOK Director |
37,167 | $2.6M |
| Jun 23, 2026 | JENNIFER COOK Director |
2,196 | $151K |
| Jun 23, 2026 | HANNAH A VALANTINE Director |
2,196 | $151K |
| Jun 22, 2026 | HANNAH A VALANTINE Director |
2,808 | $191K |
| Jun 15, 2026 | JENNIFER COOK Director |
90,240 | $6.0M |
| May 21, 2026 | NEIL KUMAR Director, Officer |
26,103 | $1.8M |
| May 18, 2026 | THOMAS TRIMARCHI Officer |
13,651 | $888K |
| Apr 9, 2026 | KUMAR HALDEA REVOCABLE TRUST U/A DTD 12/19/2018 Director, Officer |
120,000 | $8.9M |
| Mar 13, 2026 | KUMAR HALDEA FAMILY IRREVOCABLE TRUST Director, Officer |
140,000 | $9.5M |
| Mar 10, 2026 | HANNAH A VALANTINE Director |
8,671 | $624K |
| Mar 4, 2026 | ANDREA ELLIS Director |
64,921 | $4.2M |
| Feb 27, 2026 | HANNAH A VALANTINE Director |
25,484 | $1.7M |
| Feb 19, 2026 | NEIL KUMAR Director, Officer |
28,053 | $2.1M |
| Feb 17, 2026 | RANDAL SCOTT Director |
20,000 | $1.5M |
| Feb 17, 2026 | THOMAS TRIMARCHI Officer |
13,600 | $1.0M |
| Jan 8, 2026 | KUMAR HALDEA REVOCABLE TRUST U/A DTD 12/19/2018 Director, Officer |
120,000 | $8.9M |
| Jan 8, 2026 | KUMAR HALDEA FAMILY IRREVOCABLE TRUST Director, Officer |
100,000 | $7.4M |
| Dec 15, 2025 | NEIL KUMAR Director, Officer |
30,011 | $2.3M |
| Nov 20, 2025 | NEIL KUMAR Director, Officer |
26,156 | $1.7M |
| Nov 18, 2025 | ANDREW W LO Director |
55,000 | $3.6M |
| Nov 17, 2025 | ANDREW W LO Director |
40,599 | $2.7M |
| Nov 17, 2025 | RANDAL SCOTT Director |
10,000 | $664K |
| Nov 17, 2025 | THOMAS TRIMARCHI Officer |
16,934 | $1.1M |
Show the other 21 notices
From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BBIO/export.csv") into a cell.